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ABSTRACT:
The inability to faithfully segregate chromosomes in mitosis results in chromosome 
instability, a hallmark of solid tumors. Disruption of microtubule dynamics 
contributes highly to mitotic chromosome instability. The kinesin-13 family is critical 
in the regulation of microtubule dynamics and the best characterized member of 
the family, the mitotic centromere-associated kinesin (MCAK), has recently been 
attracting enormous attention. MCAK regulates microtubule dynamics as a potent 
depolymerizer of microtubules by removing tubulin subunits from the polymer end. 
This depolymerizing activity plays pivotal roles in spindle formation, in correcting 
erroneous attachments of microtubule-kinetochore and in chromosome movement. 
Thus, the accurate regulation of MCAK is important for ensuring the faithful 
segregation of chromosomes in mitosis and for safeguarding chromosome stability. In 
this review we summarize recent data concerning the regulation of MCAK by mitotic 
kinases, Aurora A/B, Polo-like kinase 1 and cyclin-dependent kinase 1. We propose 
a molecular model of the regulation of MCAK by these mitotic kinases and relevant 
phosphatases throughout mitosis. An ever-increasing quantity of data indicates that 
MCAK is aberrantly regulated in cancer cells. This deregulation is linked to increased 
malignance, invasiveness, metastasis and drug resistance, most probably due to 
increased chromosomal instability and remodeling of the microtubule cytoskeleton 
in cancer cells. Most interestingly, recent observations suggest that MCAK could be 
a novel molecular target for cancer therapy, as a new cancer antigen or as a mitotic 
regulator. This collection of new data indicates that MCAK could be a new star in 
the cancer research sky due to its critical roles in the control of genome stability 
and the cytoskeleton. Further investigations are required to dissect the fine details 
of the regulation of MCAK throughout mitosis and its involvements in oncogenesis.
INTRODUCTION: MITOSIS AND 
CHROMOSOME INSTABILITY
 The cell cycle is the series of events that take place 
in a cell resulting in its DNA replication and division. 
Numerous mechanisms exist for the control of the cell 
cycle to ensure smooth and precise progression with 
high fidelity. Mitosis, the most crucial phase in the cell 
cycle, has been one of the most active research topics in 
cell biology since its discovery and accurate description 
by  Walter  Flemming  [1].  During  mitosis  replication 
and division of the nuclear material allows one mother 
cell to give rise to two daughter cells with exact genetic 
copies. Spectacular changes occur within the cell during 
this phase such as chromatin condensation, the nuclear 
membrane  breakdown,  mitotic  spindle  assembly, Oncotarget 2011; 2:  935 - 947 936 www.impactjournals.com/oncotarget
chromosome congression and chromosome segregation. 
Correct  bipolar  spindle  formation  and  attachment  of 
chromosomes to the microtubules (MTs) are prerequisites 
for the accurate segregation of chromosomes resulting in 
an errorless chromosome complement in both daughter 
cells. The inability to faithfully segregate chromosomes in 
mitosis causes chromosome instability (CIN), a hallmark 
of solid tumors. It is becoming increasingly clear that CIN 
is not simply a passenger phenotype but likely plays a 
causative role in a substantial proportion of malignancies 
[2].  Moreover,  CIN  positively  correlates  with  poor 
patient prognosis, indicating that reduced mitotic fidelity 
contributes to cancer progression by increasing genetic 
diversity  among  tumor  cells  [3,4].  Disruption  of 
microtubule  dynamics  in  the  mitotic  spindle  generates 
mitotic  chromosomal  instability,  commonly  caused  by 
the persistent mal-oriented attachment of chromosomes to 
spindle MTs. Microtubule dynamics, mediated by highly 
coordinated  dynamic  growth  and  shrinkage,  governs 
both chromosome bi-orientation and segregation during 
cell division [5]. The kinesin-13 family members of MT 
depolymerizers  play  essential  roles  in  controlling  MT 
dynamics [6-12]. 
MITOTIC CENTROMERE-ASSOCIATED 
KINESIN (MCAK) AND THE KINESIN-13 
FAMILY 
 Unlike other kinesins, the members of the kinesin-13 
family do not use the energy from ATP turnover to move 
directionally along MTs but, instead, depolymerize them 
by disassembling tubulin subunits from the polymer end 
[13,14]. This family is characterized by the localization of 
the conserved kinesin motor domain in the middle of the 
polypeptide [15]. Variable numbers of kinesin-13 family 
members exist in invertebrate species, such as Klp10A, 
Klp59C, and Klp59D in Drosophila melanogaster [16]. In 
mammals, three unique genes corresponding to kinesin-13 
family members have been identified: Kif2A [17], Kif2B 
[18] and Kif2C or mitotic centromere-associated kinesin 
(MCAK) [19]. Kif2A is localized mainly at the centrosome 
and contributes to bipolar spindle assembly and MT flux, 
whereas  Kif2C/MCAK  is  found  to  be  localized  at  the 
centromere and regulates MT turnover at the kinetochore 
[6,11,16,20,21]  and also at the  plus-ends  of  interphase 
and mitotic astral MTs [22-24]. Kif2B has been less well 
studied. However, it has recently been shown that Kif2B 
localizes  to  centrosomes,  spindle  MTs,  kinetochores 
and the midbody, and is important for spindle assembly, 
chromosome movement and cytokinesis [8]. Kif24, the 
fourth  member  of  the  kinesin  family-13,  localizes  to 
centrioles and has recently been implicated in ciliogenesis 
[25].
 MCAK/Kif2C, the founding and best-characterized 
member of the kinesin-13 family, has an extraordinarily 
high affinity for MT ends and catalytically destabilizes 
MTs  from  either  end  with  a  comparable  rate  [26]. 
Structurally, MCAK has an N-terminal domain, followed 
by a positively charged neck, a central catalytic motor 
domain, and a C-terminal dimerization domain [6]. The 
catalytic core of MCAK is necessary but not sufficient 
for depolymerization under physiological conditions 
and  inclusion  of  the  neck  domain  restores  full  MT 
depolymerization  activity  to  the  MCAK  core  motor 
[27].  Neutralization  of  the  positively  charged  neck  by 
site-directed mutagenesis markedly reduces enzymatic 
activity both in vivo and in vitro [28]. Additionally, the 
neck is vertically directed toward the surface of the MT 
between the protofilament groove [14]. More recently, the 
contribution of the neck domain to MCAK’s activity has 
been precisely studied by applying total internal reflection 
fluorescence (TIRF) microscopy at the single molecule 
level:  MCAK’s  positively  charged  neck  enhances  its 
delivery  to  MT  ends  by  catalyzing  the  association  of 
MCAK to MTs [29]. 
 Whilst the neck region is important, it is the core 
motor domain of MCAK that drives MT depolymerization 
most  likely  by  causing  microtubule  protofilaments  to 
adopt a depolymerization competent curved conformation. 
X-ray crystallographic studies show that the MT-binding 
surface of the core motor adopts a convex form predicted 
to match the concave shape of a curved MT protofilament 
[14,30]. Additionally,  MCAK  bound  with AMPPNP,  a 
non-hydrolysable ATP analogue, stabilizes protofilament 
curls and rings [31-34]. The currently favored model of 
how this ability to encourage curving of MT protofilaments 
translates  into  depolymerization  is  that  MCAK’s  ATP 
turnover  cycle,  in  conjunction  with  the  alteration  of 
this cycle by interaction with the MT, results in MCAK 
remaining in a weakly bound diffusion competent state 
whilst on the MT lattice but to switch into a tightly bound 
depolymerization competent state at or close to the MT 
end [35]. Here, at the MT end, MCAK can exert its curve 
inducing effect on the MT protofilaments to best advantage 
resulting in potent depolymerization activity. In accord 
with this, an MCAK-decorated bead in the presence of 
ATP can attach to the MT side, but readily slides along it 
in either direction under weak external loads. However, 
the bead is tightly captured by the MT ends and readily 
causes MT disassembly [36].
 While MCAK is found in the cytoplasm throughout 
the  cell  cycle,  it  is  highly  enriched  at  centrosomes, 
centromeres/kinetochores  and  the  spindle  midzone 
during mitosis [19,37,38]. In line with this localization, 
MCAK  influences  many  aspects  of  mitosis  such  as 
spindle  assembly,  MT  dynamics,  correct  kinetochore-
microtubule  attachments,  and  chromosome  positioning 
and segregation [11,37,39-41]. Depletion or inhibition of 
MCAK activity results in improper spindle maintenance 
and misaligned chromosomes during metaphase in 
Xenopus extract spindles and lagging chromosomes 
during  anaphase  [37-39].  Decreased  MCAK  activity Oncotarget 2011; 2:  935 - 947 937 www.impactjournals.com/oncotarget
specifically at the centromere leads to poor coordination 
of  chromosome  movement,  increased  kinetochore 
fiber  stability,  as  measured  by  acetylated  tubulin 
fluorescence, and increased lagging chromosomes [42]. 
These effects could be reversed by ectopic anchoring of 
excess MCAK to centromeres. In addition, analysis of 
lagging  chromatids  in  mammalian  Ptk2  cells  depleted 
of  centromeric  MCAK  shows  stretched  staining  of  an 
autoimmune  antibody  CREST,  a  kinetochore  marker, 
indicative of merotelic kinetochore-MT attachment [43]. 
These erroneous attachments lead to the loss or gain of 
chromosomes in daughter cells known as “aneuploidy”, 
which is characteristic of cancer cells [44]. This suggests 
that  MCAK  is  involved  in  correcting  mal-attachments 
of kinetochores to MTs prior to anaphase. Thus, precise 
control of the localization and activity of MCAK is crucial 
for maintaining genetic integrity during mitosis. 
 One mechanism by which MCAK is regulated is by 
association with cofactors such as ICIS (Inner Centromere 
Kin I Stimulator) [45], hSgo2 [46], EB1 [22,24,47] and 
TIP150  [48].  More  interestingly,  an  increasing  body 
of data is emerging suggesting that the activity and 
localization of MCAK is regulated via phosphorylation 
by important mitotic kinases.
REGULATION OF MCAK BY AURORA B
  Aurora  B  kinase  is  the  catalytic  subunit  of  the 
chromosome passenger complex (CPC), which contains 
INCENP, borealin and survivin and is mobile throughout 
mitosis:  the  CPC  is  found  at  the  chromosome  arms, 
the  inner  centromere  and  the  midzone  [49].  The  CPC 
regulates many events in mitosis, including chromosome 
congression,  kinetochore-microtubule  attachments, 
spindle checkpoint control and chromosome segregation, 
by  phosphorylating  distinct  sets  of  substrates  [50,51]. 
The CPC is responsible for recruiting several groups of 
proteins to the kinetochore/centromere at metaphase: outer 
kinetochore  proteins  involved  in  the  spindle  assembly 
checkpoint (SAC) including Mad1, Mad2, Bub1, BubR1, 
Mps1  and  Cenp-E  [52-54];  proteins  responsible  for 
microtubule-kinetochore  interactions,  such  as  Cenp-E, 
Ndc80,  Knl1,  Mis12,  Zwilch,  p150Glued,  Dam1  and 
Plk1 [55-57]; and inner centromeric proteins such as the 
Shugoshin  family  proteins  Sgo1  and  Sgo2  [46,56,58]. 
Thus,  the  CPC  is  a  critical  regulator  of  centromere/
kinetochore functions [59]. Most notably, Aurora B kinase 
is required for correcting erroneous MT attachments at 
kinetochores. 
  In  the  search  for  a  molecular  understanding  of 
the  mechanism  of  action  of Aurora  B,  several  groups 
have  focused  on  the  interaction  of  Aurora  B  with 
MCAK.  Three  high  profile  studies  have  shed  light  on 
MCAK’s regulation by Aurora B [60-62]. Using in vitro 
phosphorylation and mass spectroscopy, several sites in 
the N-terminus and the neck domain of MCAK have been 
shown to be phosphorylated by Aurora B [60-62]. Further 
immunoblotting  and  immunofluorescence  staining 
confirm T92 in Chinese hamster MCAK [61] and S196 in 
Xenopus MCAK [60] are phosphorylated during mitosis 
in  living  cells.  Aurora  B  phosphorylation  of  MCAK 
strongly inhibits its ability to destabilize MTs [60-62]. In 
particular, phosphorylation at S196 appears critical to this 
activity [60]. Moreover, inhibition of Aurora B activity 
blocks  MCAK  accumulation  at  centromeres  [60,61]. 
Microinjection  of  anti-phospho-S196  antibodies  causes 
misalignment of chromosomes at metaphase in Xenopus 
egg extracts and delays chromosome congression to the 
metaphase  plate  in  cells  [61].  Intriguingly,  phospho-
mimetic  MCAK  concentrates  at  the  inner  centromere, 
whereas  unphosphorylated  MCAK  prefers  a  more 
distal  location [61]. These  data  indicate that Aurora  B 
phosphorylation both positively and negatively regulates 
MCAK activity by positively influencing the localization 
of MCAK to the centromere and negatively controlling its 
MT destabilizing activity. Interfering with this regulation 
generates defects in spindle structure and chromosome 
movements in mitosis [60-62]. A fourth important study 
has further dissected regulation of MCAK by Aurora B, 
suggesting  that  Aurora  B-dependent  chromosome  arm 
and centromere localization is regulated by a distinct two-
site  phosphorylation  mechanisms: T95  phosphorylation 
facilities  MCAK’s  association  with  chromosome  arms, 
whereas  phosphorylation  of  S196  causes  MCAK  to 
dissociate from chromosome arms and negatively affects 
its catalytic activity of MCAK [63]. 
 Aurora B is the master regulator of the merotelic 
resolution pathway that recruits and regulates proteins to 
correct chromosome-kinetochore mal-attachment [59,64]. 
Aurora B is required to release improper MT attachments 
and MCAK participates in this process [43,65]. However, 
how Aurora B-mediated suppression of MCAK activity 
can contribute to the correction of improper attachments, 
is counter-intuitive. Several working models have been 
suggested to explain this issue. It is proposed that the 
ratio of MCAK/pS196 MCAK is crucial for this function, 
based on the data that the ratio of MCAK/pS196 MCAK 
is higher at merotely sites than at properly attached 
centromeres, implying MCAK is more active at merotely 
sites [66]. A second interesting idea is that kinetochore-
associated MCAK may regulate the attachment status not 
solely by releasing the attachment, but rather by loosening 
the MTs ends embedded in the kinetochore to alter MT 
binding affinity [8,42]. A third model proposes a so called 
gradient distribution of Aurora B: when tension across 
kinetochores is established at metaphase, the extent of the 
Aurora B activity gradient across sister kinetochore pairs 
is reduced, inhibition of MCAK by Aurora B is therefore 
relieved, and active MCAK acts to promote MT dynamics 
necessary  to  correct  mal-orientated  chromosomes  [10]. 
More  studies  are  warranted  to  precisely  delineate  how 
MCAK  regulation  by Aurora  B  acts  to  correct  and/or Oncotarget 2011; 2:  935 - 947 938 www.impactjournals.com/oncotarget
prevent mal-attachments in mitosis.
REGULATION OF MCAK BY AURORA A
 Aurora A, another member of the Aurora kinase 
family,  plays  many  roles  in  mitosis  mainly  related  to 
centrosome functions and spindle assembly. It localizes 
to centrosomes and spindle poles and drives centrosome 
maturation,  separation  and  bipolar  spindle  assembly 
[67-69]. Aurora A associates with several co-activators 
including  BORA  and  TPX2  during  cell  division  that 
dictate its localization, activation and substrate preference 
[70,71]. Selective inhibition of Aurora A leads to abnormal 
mitotic spindles and chromosome segregation defects 
[72,73],  indicating  that Aurora A-associated  activity  is 
critical for spindle formation and spindle dynamics during 
mitosis.
  Interestingly,  several  reports  associate  Aurora  A 
with MCAK function and localization. In mitotic U2OS 
cells in the absence of Aurora A, MCAK is decreased at 
spindle poles, whereas ch-TOG (colonic hepatic tumor-
overexpressed gene), a functional antagonist of MCAK, 
is increased in mitotic U2OS cells, leading to extra-poles 
formation [74]. It has also been shown, using Xenopus egg 
extracts to form spindles in the absence of chromatin and 
centrosomes, that Aurora A controls MCAK’s localization 
and activity [75]. This regulation is important to focus MTs 
at aster centers and to facilitate the transition from asters 
to  bipolar  spindles.  Additionally,  MCAK  co-localizes 
with NuMA and XMAP215 at the center of Ran asters, 
where  its  activity  is  regulated  by Aurora A-dependent 
phosphorylation  of  S196,  which  contributes  to  proper 
pole focusing. MCAK localization at spindle poles is also 
controlled via S719 phosphorylation by Aurora A, which 
positively enhances bipolar spindle formation. This study 
suggests that Aurora A targets MCAK to spindle poles 
via phosphorylation on S719, and regulates its activity 
by phosphorylation at S196. It is however unclear how 
this phosphorylation of MCAK by Aurora A directs its 
localization. These results indicate that Aurora A regulates 
the  localization  of  MCAK  at  spindle  poles  and  that 
MCAK is involved in spindle pole integrity. However, 
the  molecular  mechanism  by  which Aurora A  impacts 
MCAK’s localization has not been described. Furthermore, 
whether this regulation of MCAK by Aurora A also affects 
its catalytic activity remains undefined. Nevertheless, as 
described above, the localization and activity of MCAK 
at the centromere/kinetochore are controlled by Aurora 
B kinase, whereas the localization and activity at spindle 
poles appear to be regulated by Aurora A.
REGULATION OF MCAK BY CYCLIN-
DEPENDENT KINASE 1 (CDK1)
 Cdk1/cyclin B1 is a kinase essential for the initiation 
of mitosis. We have found that the phenotype of depleting 
cyclin B1, the regulatory subunit of Cdk1, is reminiscent 
of that of the inhibition of MCAK. Moreover, MCAK and 
Cdk1 co-localize at centrosomes and they are associated 
with  each  other  in  mitosis.  Further  work  shows  that 
Cdk1/cyclin  B1  regulates  the  function  and  localization 
of MCAK by phosphorylating T537 in the core domain 
[76].  This  phosphorylation  of  MCAK  by  Cdk1/cyclin 
B1 attenuates its MT-destabilizing activity in vitro and in 
vivo. Phosphorylation of MCAK by Cdk1 promotes the 
release of MCAK from centrosomes and is required for 
proper spindle formation. Furthermore, interfering with 
the regulation of MCAK by Cdk1 causes dramatic defects 
in spindle formation and in chromosome positioning. 
Unlike Aurora B, Cdk1 phosphorylates only one residue 
T537 in the core domain of MCAK. T537 is located in the 
L12 loop, which is immediately C-terminal to the α4 helix 
of the core domain in MCAK. It has been suggested that 
the α4 helix is directly involved in binding to a curved 
conformation of tubulin at the ends of MT protofilaments 
and  thereby  facilitates  depolymerization  [14].  It  is 
therefore possible that the introduction of a negative charge 
adjacent to the α4 helix via phosphorylation of T537, could 
disrupt the interaction of MCAK with the MT end, thus 
causing attenuation of MCAK’s MT-destabilizing activity. 
Further investigations are required to define precisely how 
MCAK is coordinated and controlled by Cdk1/cyclin B1 
at centrosomes/spindle poles.
REGULATION OF MCAK BY POLO-LIKE 
KINASE 1(PLK1)
 Five mammalian Plk family members have been 
identified  to  date,  Plk1-5  [77].  Plk1,  the  best  studied 
member  of  the  family  [78],  is  a  key  regulator  of  cell 
division in eukaryotic cells. Plk1 controls multiple events 
in mitosis such as centrosome maturation, bipolar spindle 
formation,  stable  microtubule-kinetochore  attachment, 
cohesion  dissociation,  chromosome  alignment  and 
segregation, and cytokinesis [79,80]. In accord with its 
diverse functions, the localization of Plk1 during mitosis is 
dynamic. Plk1 first associates with centrosomes in prophase 
before  it  localizes  to  spindle  poles  and  kinetochores 
in  prometaphase  and  metaphase.  In  anaphase,  Plk1  is 
recruited to the central spindle and finally accumulates 
at  the  midbody  in  telophase.  Proteomic  studies  using 
oriented peptide libraries have shown that the polo-box 
binding domain (PBD) at the C-terminus of Plk1, dictates 
the localization of this kinase to cellular structures 
[81,82].  This  domain  binds  to  specific  phosphorylated 
sequence motifs that are created by other priming kinases 
or  are  self-primed  by  Plk1  itself,  thus  providing  an 
efficient mechanism to regulate localization and substrate 
selectivity  in  time  and  space  [83,84].  Thus,  the  PBD 
provides  a  much  more  compelling  site  to  specifically 
inhibit Plk1 [85,86]. Plk1 is a proliferation marker and 
highly expressed in a broad spectrum of human tumors, Oncotarget 2011; 2:  935 - 947 939 www.impactjournals.com/oncotarget
which is associated with prognosis of tumor patients and 
suggestive of its involvement in oncogenesis [77,87,88]. 
Interestingly, Plk1 expression is affected by several drugs, 
like  metformin  [89].  Despite  intensive  investigations, 
the role of the multifaceted Plk1 in oncogenesis remains 
incompletely understood at the molecular level. 
 It has been revealed that Plx1, the analogue of Plk1 
in  Xenopus,  phosphorylates  the  N-terminal  region  (aa 
2-116) of MCAK in kinase assay in vitro [90]. Moreover, 
priming MCAK by Plx1 produced robust phosphorylation 
on T95 site but little on S196 in MCAK by Aurora B, 
suggesting that this is the key event to allow Aurora 
B  to  phosphorylate  the  residue  T95  [90].  Since  T95 
phosphorylation is critical for MCAK’s localization on 
chromosome arms in prophase and prometaphase [63], 
the data suggest that Plx1 could be the priming kinase 
for Aurora B to promote the localization of MCAK to the 
chromosome arms. This is an interesting finding indicative 
of a collaborative action of Plk 1 and Aurora B in the 
regulation of MCAK. It remains to be investigated which 
residue in the N-terminus of MCAK is phosphorylated by 
Plk1 and how this modification facilitates phosphorylation 
of T95 by Aurora B. It is also necessary to define if the 
same takes place in vivo and whether this collaboration 
model could also be valid for mammalian cells.
 A second study dealing with MCAK’s regulation 
by Plk1 has recently been reported [91]. Based on the 
data from in vitro phosphorylation assay and mass 
Figure 1: Scheme of MCAK regulation by mitotic kinases and phosphatases. Current data suggest that MCAK undergoes 
complex spatiotemporal regulation by mitotic kinases Aurora A/B, Plk1 and Cdk1/cyclin B1. In early mitosis, S196 phosphorylation 
of MCAK by Aurora A reduces its activity and facilitates the transition from asters to bipolar spindles, whilst MCAK localization at 
spindle poles is regulated through another Aurora A phosphorylation site S719 and positively enhances bipolar spindle formation. Cdk1 
phosphorylates T537 in the core domain of MCAK, attenuates its activity, and drives MCAK from spindle poles to other locations 
and promotes proper spindle formation. Thus, the localization and activity of MCAK at centrosomes and spindle poles appear to be 
mainly controlled by coordinated regulation of Aurora A and Cdk1. In prometaphase, the localization of MCAK to the chromosome 
arms is controlled by Aurora B, possibly supported by Plk1. In metaphase, the localization and activity of MCAK at the centromeres and 
kinetochores are finely regulated via phosphorylation by Aurora B. By contrast, Plk1 promotes the activity of MCAK at kinetochores. Co-
ordinated regulation of MCAK by Aurora B and Plk1 might fine-tune its activity for correction of mal-attachments. Finally, in anaphase, 
the activity of MCAK is further coordinated and controlled by Aurora B and Plk1, possibly balanced by phosphatases. 
Aurora A phosphorylated MCAK
Cdk1 phosphorylated MCAK
Aurora B posphorylated MCAK
Plk1 phosphorylated of MCAK
 Deposphorylated and activated MCAK
prophase prometaphase
anaphase metaphase
Figure 1: Mitotic Regulation of MCAKOncotarget 2011; 2:  935 - 947 940 www.impactjournals.com/oncotarget
spectrometry,  six  serines  (S592,  S595,  S621,  S632, 
S633 and S715) at the C-terminus of MCAK have been 
identified as substrates of Plk1. In contrast to regulation 
by Aurora A/B  and  Cdk1,  phosphorylation  of  MCAK 
by Plk1 stimulates the MT depolymerization activity of 
MCAK in cells. Overexpression of a Plk1 phosphomimetic 
MCAK mutant causes a dramatic increase in misaligned 
chromosomes and in multipolar spindles in mitotic 
cells,  while  overexpression  of  a  non-phosphorylatable 
MCAK mutant results in defects in anaphase with sister 
chromatid bridges. These data imply that the enhanced 
enzymatic  activity  of  MCAK  by  Plk1  is  required  for 
correction of mal-attachment of MTs. On the other hand, 
a temporal dephosphorylation of MCAK is of importance 
for  proper  chromosome  alignment  and  bipolar  spindle 
formation. This study also suggests that phosphorylation 
of MCAK by Plk1 may alter its molecular conformation. 
Further  investigations  are  warranted  to  elucidate  the 
structural  basis  of  this  potential  Plk1-induced  MCAK 
conformational change. Moreover, it will be interesting 
to  identify  the  major  phosphorylation  site  in  MCAK’s 
C-terminus by Plk1 and to dissect the function of each 
phosphorylation site. It may be that Plk1 acts in a similar 
way  as  Aurora  B  phosphorylates  different  residues  in 
MCAK  controlled  both  temporally  and  spatially  to 
coordinate MCAK’s function at various stages of mitosis. 
Furthermore, since both the N-terminus in Xenopus and 
the C-terminus in mammalian cells are phosphorylated by 
Plx1 and Plk1, respectively, it remains possible that both 
regions of MCAK are regulated by Plk1 at different stages 
in vivo. It is tempting to speculate that the regulation of 
MCAK  by  Plk1  will  exhibit  a  more  complex  picture, 
even than Aurora B, with various functions depending 
on different subcellular locations and on different time 
points in mitosis. Moreover, Santamaria and colleagues 
have investigated the Plk1-dependent phosphoproteome 
of the human mitotic spindle using an elegant method of 
isotope labeling of amino acids in cell culture [92]. One 
of the most interesting findings is that MCAK’s spindle 
association is highly dependent on Plk1 activity [92]. It 
remains to be explored if Plk1 regulates this association 
directly or indirectly.
ORCHESTRATED REGULATION OF MCAK 
BY MITOTIC KINASES/PHOSPHATASES 
  During  the  cell  division  cycle,  mitotic  entry, 
centrosome  separation,  spindle  assembly,  chromosome 
congression/segregation,  and  cytokinesis  must  all  be 
tightly coordinated to ensure that the two daughter 
cells inherit the same genetic material. Central to this 
coordination are several protein kinases including Cdk1, 
Plk1, Aurora A and Aurora B, which regulate the functions 
of many molecules in a precisely coordinated and finely 
tuned manner. Current data suggest that MCAK undergoes 
complex spatiotemporal regulation by these critical mitotic 
kinases  throughout  mitosis  (Fig.  1).  In  early  mitosis, 
the  localization  and  activity  of  MCAK  at  centrosomes 
and  spindle  poles  appear  to  be  mainly  controlled  by 
the coordinated regulation of Aurora A and Cdk1. S196 
phosphorylation  of  MCAK  by  Aurora  A  reduces  its 
activity and facilitates the transition from asters to bipolar 
spindles, whilst MCAK localization at spindle poles is 
regulated through another Aurora A phosphorylation site 
S719 and positively enhances bipolar spindle formation. 
Cdk1 phosphorylates T537 in the core domain of MCAK, 
reducing its activity, and driving MCAK from the spindle 
poles to other locations, thus promoting proper spindle 
formation. In prometaphase, the localization of MCAK to 
the chromosome arms seems to be controlled by Aurora 
B, possibly aided by Plk1. In metaphase, the localization 
of MCAK at the centromeres and kinetochores is finely 
regulated via phosphorylation by Aurora B. In this process, 
the activity of MCAK at the centromeres/kinetochores is 
potentially positively promoted by Plk1-mediated activity 
to fine-tune the regulation by Aurora B. This coordinated 
regulation may allow efficient correction of mal-attached 
microtubule-kinetochore.  Finally,  in  anaphase,  the 
activity of MCAK is controlled by Aurora B and Plk1, 
balanced possibly by phosphatases. The picture of MCAK 
regulation by mitotic kinases (Fig. 1) is still immature and 
more studies are needed to complete the picture. The final 
picture displaying the temporal and spatial regulation of 
MCAK in mitosis may be more complex than we had 
previously imagined.
  Specific  phospho-antibodies  targeting  each 
phosphorylation  site  by  each  mitotic  kinase  will  be  of 
great use in deciphering when, where and by which kinase 
MCAK  is  phosphorylated  throughout  various  mitotic 
stages. The specific small molecule compounds targeting 
Cdk1, Aurora A, Aurora B or Plk1 will also be useful to 
uncover the timing and location of each phosphorylation, 
and to study the exact impact of each kinase on MCAK 
in  mitosis.  Moreover,  current  data  imply  that  timely 
dephosphorylation is also necessary for the proper mitotic 
function of MCAK, as phospho-mimetic forms of MCAK 
induce many defects in mitosis [76,91]. Recent work has 
exposed the conserved serine-threonine phosphatases PP1 
and PP2A as key regulators of various mitotic processes. 
PP1  is  known  to  both  localize  to  kinetochores  and  to 
reverse  phosphorylation  generated  by  Aurora  B  [55], 
indicating  that  PP1  is  a  prime  candidate  for  opposing 
Aurora  B-dependent  maintenance  of  kinetochore 
integrity.  Indeed,  kinetochore  disassembly  following 
Aurora B inhibition is prevented by inhibiting PP1 [55]. 
Thus, the proper regulation of MCAK at the centromeres/
kinetochores likely depends on a biased turnover between 
kinases and their counteracting phosphatases. Intensive 
investigations  are  required  to  understand  this  network 
of  regulation.  It  is  also  of  importance  to  determine  if 
interaction partners of MCAK are regulated by the same 
mitotic kinases, which will further dissect the molecular Oncotarget 2011; 2:  935 - 947 941 www.impactjournals.com/oncotarget
network of MCAK regulation in mitosis. Finally, there 
remains much work still to do to define the functional 
relationship among the three members of the Kinesin-13 
family found in mammalian cells and also with members 
of  other  kinesin  families,  such  as  the  family-14  and 
family-8 [93,94].
MCAK IN ONCOGENESIS: ASSOCIATION 
OF MCAK WITH CANCER DEVELOPMENT
 MCAK is important for proper spindle formation, 
correction  of  aberrant  attachments  of  microtubule-
kinetochore and for chromosome segregation. To 
accomplish  this,  the  activity  and  localization  of 
MCAK  must  be  closely  regulated  by  various  kinases 
and  phosphatases  in  a  finely  orchestrated  manner. 
Unfortunately,  mitotic  kinases  and  phosphatases  can 
become  unregulated  resulting  in  abnormal  mitosis, 
chromosome instability and ultimately transformation. By 
the same logic deregulation of MCAK may play a role in 
cancer development. 
  Indeed,  it  has  been  reported  that  MCAK  is  one 
of dozens of trans-activated genes in a genome-wide 
expression analysis of 81 breast cancer tissues by means of 
a combination of cDNA microarray and laser microbeam 
microdissection  [95].  Further  analysis  demonstrated 
that  MCAK  is  overexpressed  in  primary  breast  cancer 
tissues  as  well  as  in  cell  lines  [96,97].  In  addition, 
MCAK expression is significantly suppressed by ectopic 
introduction of p53 [97], suggesting that highly expressed 
MCAK might be involved in breast cancer development. 
This  elevated  expression  of  MCAK  is  observed  not 
only  in  breast  cancer  but  also  in  gastric  cancer  [98], 
and enhanced MCAK expression is significantly linked 
to lymphatic invasion, lymph node metastasis and poor 
prognosis  in  gastric  cancer  patients  [98].  Furthermore, 
this  observation  is  underscored  by  a  study  based  on 
120  colorectal  cancer  samples:  MCAK  expression  is 
significantly higher at both the mRNA and protein levels, 
compared  to  paired  corresponding  normal  tissues,  and 
this elevated expression level is markedly correlated 
with lymph node metastasis, venous invasion, peritoneal 
dissemination,  Dukes’  classification  and  poor  survival 
rate  [99].  Recently,  this  observation  has  been  further 
strengthened by a study containing 176 samples derived 
from colorectal, pancreatic, gastric, breast and head and 
neck cancer tissues [100]. Comparing expression levels 
among cancer types, it is noted that MCAK is most strongly 
overexpressed in gastric, breast and colorectal cancer and 
less pronounced in pancreatic and head and neck cancer. 
More recently, MCAK gene has been found to be highly 
expressed in glioma samples, which is associated with 
histopathological grades [101]. Taken together, the data 
highlight that MCAK is aberrantly regulated in cancer 
cells  and  enhanced  MCAK  levels  are  associated  with 
cancer  progression,  invasiveness,  metastasis  and  poor 
prognosis,  particularly  in  breast,  gastric  and  colorectal 
cancer.
 Deregulated MCAK results in defects in spindle 
formation  and  chromosome  segregation,  which  lead 
to  further  chromosomal  instability.  Being  capable  of 
escaping  apoptosis  and  surviving  such  defects,  cancer 
cells  proliferate  regardless  of  chromosomal  instability, 
promoting progression of cancer cells. As described above, 
it seems p53 is involved in regulating the expression of 
MCAK [97]. Further studies are required to corroborate 
the relationship between p53 status and the MCAK level 
in  primary  cancer  tissues.  More  questions  have  to  be 
addressed:  Does  p53  directly  affect  the  transcriptional 
activation of the MCAK promoter, or indirectly via other 
transcriptional  factors?  As  microRNAs  (miRNAs)  are 
becoming more and more important in regulating mRNA 
expression of key molecules, is miRNA involved in the 
regulation  of  MCAK  mRNA  in  cancer  cells?  Or  are 
elevated levels of MCAK more ascribed to deregulated 
protein  turnover?  Intriguingly,  the  data  suggest  that 
enhanced MCAK is correlated not only with progression 
but  also  with  invasiveness/metastasis  in  cancer  cells, 
suggesting  MCAK  is  possibly  also  involved  in  the 
alteration of cell motility in cancer cells. Cell motility 
is a complex process requiring coordinated organization 
of  actin  and  MT  cytoskeletons  in  physiological  and 
pathological conditions such as cancer cell metastasis. 
It  will  be  interesting  to  understand  how  deregulated 
MCAK in cancer cells promotes migration/invasiveness/
metastasis:  Is  elevated  MCAK  able  to  reorganize  MT 
cytoskeleton  and  to  alter  the  motility  of  cancer  cells, 
in particular, in non-proliferating cancer cells? How do 
changes in MCAK levels influence tubulin expression and 
auto-regulation? Is deregulated MCAK associated with 
remodeling the environments of cancer cell including 
cell-cell  and  cell-extracellular  matrix  adhesion?  In 
addition, early steps in metastasis are often linked with 
epithelial-mesenchymal transition (EMT), a process that 
allows polarized epithelial cells into isolated, migratory 
cells with mesenchymal morphology and characteristics 
[102].  Does  deregulated  MCAK  facilitate  EMT  by 
reorganizing cell cytoskeleton, possibly coordinated with 
other  molecules/signal  pathways?  Does  the  front  line/
part of cancer tissues express more MCAK? Numerous 
questions await answers. 
  It  is  intriguing  to  note  that  highly  expressed 
MCAK  is  linked  with  invasiveness  and  metastasis  in 
colorectal cancer [99]. It is known that more than 80% 
of colorectal cancers have inactivating mutations in the 
adenomatous polyposis coli (APC), a tumor suppressor 
linked to the initiation and progression of colon cancer 
[103,104].  APC  participates  to  the  Wnt  signaling 
pathway  by  downregulating  β-catenin  and  controlling 
gene transcription and cell proliferation. Moreover, APC 
plays a key role in directed cell migration by showing its 
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to  bind  multiple  polarity  proteins  and  MT-associated 
molecules [105]. Interestingly, the APC protein mediates 
direct interactions with MTs and the MT plus-end tracking 
protein EB1 (end-binding protein 1), which promotes MT 
growth through increased rescue frequency and decreased 
catastrophe of plus-ends [106]. Interestingly, MCAK has 
also  been  reported  to  track  MT  plus-ends  [22]  and  to 
co-localize with EB1 at growing MT ends [23]. It will 
be  interesting  to  delineate  how  the  plus-end  tracking 
proteins function in colon cancer cells, with inactive APC 
and elevated MCAK, in context of the dynamics of MT 
cytoskeleton and cell motility.
INVOLVEMENT OF MCAK IN DRUG 
RESISTANCE
 Overexpression of MCAK is not only associated 
with malignance progression, but also with drug resistance. 
Taxanes, used either as single agents or in combination 
with multiple other anticancer agents, are routinely used 
for  a  wide  range  of  solid  tumors  [107].  Despite  their 
widespread use, the clinical effectiveness of taxanes is 
hampered  by  its  severe  side-effects  and  its  resistance, 
which ultimately leads to relapse and poor prognosis. 
Various  mechanisms  have  been  implicated  in  acquired 
or secondary taxane resistance [108]. It is reported that 
overexpression of MCAK confers resistance to paclitaxel 
and  epothilone  A  [109].  It  is  further  demonstrated 
that  paclitaxel  resistant  cells  resulting  from  MCAK 
overexpression displays a decrease in MT polymer and 
an  increase  in  the  frequency  of  MT  detachment  from 
centrosomes  [109].  Moreover,  loss  of  MCAK  reverses 
this  aberrantly  high  frequency  of  MT  detachment  and 
increases their sensitivity to paclitaxel [110]. The results 
indicate that MCAK affects cell sensitivity to paclitaxel 
by modulating MT morphology and dynamics.
MCAK AS A POTENTIAL MOLECULE 
TARGET FOR CANCER THERAPY
  MCAK  is  also  identified  as  a  novel  cancer 
antigen,  suggesting  the  possibility  of  cancer  specific 
immunotherapy  [98].  This  notion  is  underscored  by  a 
recent  observation  that  MCAK  is  capable  of  inducing 
spontaneous T cell responses in vivo resulting in highly 
functional MCAK-specific T cells in both patients with 
colorectal  cancer  and  healthy  donors  [100].  MCAK 
serves as an antigen is further supported by another study 
Figure 2: Summary of MCAK’s involvements in oncogenesis. In gastric, colorectal and breast cancer, MCAK is overexpressed, 
which could be contributed by defects in promoter control, mRNA stability and protein turnover, possibly associated with deregulated 
kinases/phosphatases in cancer cells. The highly expressed MCAK could result in abnormal spindle formation, erroneous attachment and 
failure in chromosome segregation, leading to chromosomal instability and promoting cancer progression. Enhanced MCAK is linked to 
invasiveness/metastasis of cancer patients, which could be caused by remodeling MT cytoskeleton and altering cell shape and migration. 
Elevated MCAK could reorganize MT morphology/dynamics and contribute to resistance of the MT binding agents. In addition, MCAK 
could be considered as a potential target for molecular intervention: either as a novel antigen, provoking immunoreaction of cancer patients, 
or as a MT regulator/modulator, in combination with other chemotherapeutic drugs. 
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showing MCAK peptides are able to induce cytotoxic T 
lymphocytes to lyse cancer cells in an HLA-A2- or HLA-
A24-restricted  manner  [111].  Together,  the  data  imply 
that  MCAK  is  possibly  a  promising  target  for  cancer 
immunotherapy for colorectal and gastric cancers.
 Targeting mitotic kinesins, such as Eg5, has been 
regarded as a promising strategy for cancer therapy [112]. 
The unique ability of MCAK to regulate MT dynamics 
makes it a potential target for development of new drugs 
that alter spindle function [113]. It has been shown that 
malignant cell lines are more sensitive to depletion of 
MCAK, in comparison with normal cells. In addition, MT 
interfering  drug  paclitaxel  or  vinblastine  induces  more 
cytoskeleton defects in HeLa cells depleted of MCAK 
[113]. Moreover, using quantitative immunofluorescence 
and  fluorescence  recovery  after  photobleaching,  the 
differences in spindle organization is analyzed in cells 
treated  with  low  levels  of  paclitaxel,  or  with  MCAK 
inhibition [114]. Interestingly, paclitaxel treatment causes 
a  disruption  in  spindle  MT  organization  marked  by  a 
significant increase in MTs near the poles and a reduction in 
K-fiber fluorescence intensity, whereas MCAK inhibition 
triggers a dramatic reorganization of spindle MTs with a 
significant increase in astral MTs and reduction in K-fiber 
fluorescence intensity [114]. Moreover, MCAK depletion 
promotes dramatic spindle rocking in early anaphase, and 
this effect is also observed with taxol treatment [115], 
indicative of defects in cytokinesis. These data support the 
idea that combination of MCAK suppression with paclitaxel 
perturbs synergistically spindle organization, which could 
induce  severe  irreversible  mitotic  defects,  extending 
mitotic timing and leading further to mitotic catastrophe 
and apoptosis in cancer cells. These studies suggest that 
MCAK might be a good target for new drug development, 
which could be particularly useful in combination with 
currently available anti-microtubule agents. In fact, it is 
reported that one form of sulfoquinovosylacylglycerols 
(SQAGs) targets the activity of MCAK in cells [116]. It 
will be interesting to examine if the p53 status and genome 
instability influence its effectiveness [117,118]. Figure 2 
illustrates the involvement of deregulated MCAK in tumor 
development,  invasiveness/metastasis,  drug  resistance, 
and the potential for MCAK as a novel target.
CONCLUSIONS AND OUTLOOK
 The finely tuned regulation of MCAK by various 
mitotic kinases and phosphatases is essential for the 
faithful segregation of chromosomes in mitosis and for 
safeguarding  genome  stability.  Current  data  suggest 
MCAK  undergoes  complex  spatiotemporal  regulation 
during  mitosis  mainly  by  Aurora  B,  coordinated  by 
other critical mitotic kinases Aurora A, Plk1 and Cdk1/
cyclin B1. Further investigations are required to define 
the precise cross-talk networks among these kinases 
throughout  mitosis  and  their  balance  by  phosphatases. 
MCAK expression is deregulated in breast, gastric and 
colon  cancer,  which  is  highly  correlated  with  cancer 
progression, invasiveness and metastasis. However, the 
molecular  mechanisms,  which  drive  high  expression 
of  MCAK  in  those  cancers,  are  not  clear.  It  will  be 
interestingly  to  explore  the  signal  pathways,  by  which 
suppression of MCAK renders resistant cancer cells re-
sensible to taxanes. It is also important to investigate how 
overexpression of MCAK increases mobility in cancer cells 
and promotes invasiveness and metastasis. In addition, 
it will be of interest to examine whether MCAK could 
indeed serve as a new target for molecular intervention, as 
an antigen for immunotherapy, or as a mitotic regulator in 
combination with other agents interfering with mitosis. It 
will be also of clinical importance to study the correlation 
between  abnormal  activities  of  mitotic  kinases  and 
deregulated MCAK activity in primary cancers.
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